# RASolve 301: HCP commentary report

> 97 verified statements (13 from clinicians verified by NPI or staff page) from 24 commentary sources · 7 findings · updated Oct 29, 2026

## Report

- Trial: RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC
- NCT ID: NCT06881784
- Registry: https://clinicaltrials.gov/study/NCT06881784
- Sponsor: Revolution Medicines, Inc.
- Phase: Phase 3
- Status: Recruiting
- Drugs: docetaxel
- Indications: Non-small cell lung cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-10-29
- Last checked: 2026-10-29
- Release hash: 7342ec228c58be7f15a80f5b0fe06a86eaf85b87a88a5dad36f7bd28cd685c20

## Counts

- HCP commentary sources screened: 36
- Sources cited by verified statements: 24
- Verified statements: 97
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 13
- Findings: 7
- People found in screened sources: 11
- Voices cited: 11
- Cited voices identity-verified: 9
- Organisational or shared accounts (not counted as people): 7

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

Clinician commentary on RASolve 301 in the sources reviewed for this edition leads to one open question: Does daraxonrasib deliver a durable, tolerable advantage over docetaxel, and which subtype and sequencing uncertainties will the evidence resolve? Its leading findings: (1) optimism remains conditional on clearing the docetaxel evidence threshold. (2) the safety debate depends on attribution, population and the burden of staying on treatment. (3) the most clinically attractive subgroup is also the focus of methodological skepticism. 4 more findings follow. 36 sources screened, 24 cited; not all HCPs or all public discussion.

## Open Medical Affairs question

Does daraxonrasib deliver a durable, tolerable advantage over docetaxel, and which subtype and sequencing uncertainties will the evidence resolve?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Optimism remains conditional on clearing the docetaxel evidence threshold
- F2. The safety debate depends on attribution, population and the burden of staying on treatment
- F3. The most clinically attractive subgroup is also the focus of methodological skepticism
- F4. The 200 mg choice is interpreted as dose optimization rather than maximal dosing
- F5. Broader RAS targeting generates enthusiasm but leaves subtype, CNS and sequencing questions open
- F6. Trial access, guideline reporting and approval must remain separate messages
- F7. Combination enthusiasm is largely relayed rationale, not established NSCLC combination evidence

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 15 | 13 | 8 | 7 | recorded | 2 |
| F2 | 23 | 25 | 8 | 8 | recorded | 3 |
| F3 | 29 | 34 | 12 | 9 | recorded | 3 |
| F4 | 10 | 13 | 9 | 7 | none recorded | 2 |
| F5 | 19 | 20 | 10 | 9 | recorded | 3 |
| F6 | 7 | 11 | 4 | 3 | none recorded | 3 |
| F7 | 4 | 4 | 3 | 3 | none recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 8 | 2 | 0 | 2 | 3 | 15 | 1 | 7 posts and articles, 1 podcast or video | yes |
| F2 | 13 | 4 | 0 | 1 | 5 | 27 | 1 | 7 posts and articles, 1 podcast or video | yes |
| F3 | 8 | 7 | 0 | 0 | 14 | 36 | 0 | 11 posts and articles, 1 podcast or video | yes |
| F4 | 5 | 1 | 0 | 1 | 3 | 14 | 1 | 8 posts and articles, 1 podcast or video | yes |
| F5 | 11 | 5 | 0 | 1 | 2 | 24 | 0 | 9 posts and articles, 1 podcast or video | yes |
| F6 | 2 | 0 | 0 | 1 | 4 | 11 | 1 | 3 posts and articles, 1 podcast or video | yes |
| F7 | 1 | 1 | 0 | 0 | 2 | 5 | 0 | 3 posts and articles | yes |

### Trial dimensions

- Primary endpoint: Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C): F1 (2 shared claims), F2 (2 shared claims), F3 (6 shared claims), F4 (3 shared claims), F5 (3 shared claims)
- Primary endpoint: Overall survival (OS) in the RAS G12X-C population: F1 (4 shared claims), F2 (3 shared claims), F3 (8 shared claims), F4 (3 shared claims), F5 (2 shared claims)
- Secondary endpoints: F1 (2 shared claims), F2 (2 shared claims), F3 (12 shared claims), F4 (4 shared claims), F5 (4 shared claims), F7 (1 shared claims)
- Population and setting: F1 (1 shared claims), F3 (2 shared claims), F5 (13 shared claims)
- The comparison: F1 (10 shared claims), F2 (3 shared claims), F3 (6 shared claims), F4 (3 shared claims), F5 (1 shared claims), F6 (1 shared claims)
- Safety and tolerability: F1 (2 shared claims), F2 (21 shared claims), F3 (2 shared claims), F4 (6 shared claims), F5 (1 shared claims), F7 (1 shared claims)
- Design and conduct: F1 (7 shared claims), F2 (1 shared claims), F3 (2 shared claims), F4 (1 shared claims), F5 (1 shared claims), F6 (1 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 7 | Titles free |
| Detailed analysis | 8 sections | Paid |
| Verified statements with short source quotes and links | 97 | Paid |
| Trial aspects mapped | 14 | Free |
| Sources with links | 24 | Counts free |
| Speaker attribution for cited voices | 11 | Paid |

## Trial aspects

14 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C) | discussed | 9 | 9 |
| Primary endpoint: Overall survival (OS) in the RAS G12X-C population | discussed | 10 | 9 |
| Secondary endpoints | discussed | 16 | 11 |
| Population and setting | discussed | 13 | 8 |
| The comparison | discussed | 16 | 11 |
| Safety and tolerability | discussed | 25 | 9 |
| Design and conduct | discussed | 7 | 6 |
| Dose optimization and the interpretation of 200 mg | discussed | 10 | 9 |
| Post-G12C-inhibitor sequencing, CNS activity and resistance | discussed | 8 | 5 |
| Clinical meaning of active-state, multi-selective RAS targeting | discussed | 8 | 4 |
| Credibility and generalizability of the early-phase subgroup | discussed | 20 | 5 |
| Patient support, rash prevention and sustained treatment | discussed | 10 | 2 |
| Local trial availability, guideline reporting and regulatory access | discussed | 8 | 4 |
| Combination rationale versus regimen-specific clinical evidence | discussed | 3 | 3 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 27 | 18 |
| LinkedIn posts | 4 | 4 |
| Bluesky threads | 4 | 1 |
| YouTube | 1 | 1 |

- Screened window: 2025-03-27 to 2026-10-13
- Cited window: 2025-03-27 to 2026-10-13
- Retrieved: 2026-10-29

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC
- Registry: NCT06881784 (https://clinicaltrials.gov/study/NCT06881784)
- Study IDs: RMC-6236-301
- Sponsor: Revolution Medicines, Inc.
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Recruiting
- Enrollment: 590 (estimated)
- Start: 2025-05-06 (actual)
- Primary completion: 2027-12-01 (estimated)
- Primary endpoint: Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C) (Up to approximately 4 years)
- Primary endpoint: Overall survival (OS) in the RAS G12X-C population (Up to approximately 4 years)
- Intervention: daraxonrasib (drug)
- Intervention: docetaxel (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on antitumor activity and dose-dependent response in previously treated RAS-mutant non-small cell lung cancer.
- Not yet captured in this edition: a view on the evidence needed to validate daraxonrasib’s response signal in previously treated advanced RAS-mutant NSCLC.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 20 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The discussion summarized here does not establish the prevalence of any view among HCPs. Social posts, repeated material and third-party relays cannot be counted as independent clinician endorsements.
- Some potentially relevant posts and video passages were not fully assessed. Discussion using different names, spellings or no trial name may be underrepresented.
- No protocol or results publication for NCT06881784 was available. The efficacy and safety results discussed by the authors are earlier-phase findings, not RASolve 301 outcomes.
- The identity of several public authors is unverified, and some clinical roles or displayed credentials are not confirmed. The educational video cannot be attributed to named HCPs.
- Official regulatory and guideline documents were not available to confirm the reported approval, guideline and reimbursement statements. Those statements remain attributed to their sources and dates.
- Early efficacy, durability, safety and discontinuation figures differ in population, dose or definition across sources. The report does not harmonize them into a common dataset or resolve numerical inconsistencies.
- Post dates do not independently establish presentation or readout dates, changing opinions or disagreement across clinical settings.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-29: current edition

Last checked for new commentary 2026-10-29. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (97 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (9 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/rasolve-301-nct06881784
- Agents: POST https://www.erudio.com/api/orders with {"report": "rasolve-301-nct06881784", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=rasolve-301-06881784

## Cite

Erudio Health. RASolve 301 (NCT06881784): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 29, 2026. https://www.erudio.com/reports/rasolve-301-nct06881784

## Machine access

- JSON: https://www.erudio.com/reports/rasolve-301-nct06881784.json
- Markdown: https://www.erudio.com/reports/rasolve-301-nct06881784.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "rasolve-301-06881784"}`